What Investors Got Wrong About Afya Before The Drop

If you had looked at Afya on 1 January 2026 and decided to sit it out while analysts argued over whether telehealth and Brazil’s aging population would reshape its medical education model, the choice may feel different now. Investors who held Afya from the start of the year are down 26.7%, including dividends. What early warning or overconfident assumption in those bullish and bearish narratives would you want to stress test today?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Afya is not the only name tied to this theme. Zero in on 35 healthcare AI stocks and compare how each one is priced.

The Two Stories Afya Investors Were Weighing

The shares cost US$15.41 at the start of the period, and anyone looking at Afya then had to decide which story felt more realistic.

On the optimistic side, the bullish narrative put Fair Value at US$25.04. That view leaned on Brazil's physician shortage and demographic trends supporting strong medical education demand, plus an assumption that Afya's centralized model could lift profit margins from 19.6% to 32.3% by 2028.

The more cautious camp set Fair Value at US$14.09. That thesis focused on the risk that AI powered and online medical education and new accredited competitors would erode Afya's traditional campus demand and weaken tuition pricing power over time.

What The Afya Evidence Changed, And What It Did Not

The binding merger agreement between Afya and Yduqs directly spoke to the bullish claim that Afya could consolidate Brazilian medical education. Q2 2026 results, with revenue at R$972.1m and net income at R$197.1m, alongside a net margin of 20.3% versus 18.7% a year earlier, pointed toward healthier profitability. Together, they cut both ways for the original cases.

The real hinge here was scale and pricing power. For any other education stock, watch how reported margins, seat authorisations and consolidation moves line up with earlier promises about efficiency and demand.

Afya Today, And What The Fall Now Asks You To Believe

Afya trades at US$10.5 today, after a 26.7% loss from the start of the year. The selected Narrative’s Fair Value sits above the current price, tied to how effectively Afya and Yduqs can turn planned scale into cash generation.

The fall only becomes an opening if you think Afya can deliver the merger synergies, AI upgrades and education breadth that underpins this Narrative. A buyer now is really judging whether that combined platform can support stronger earnings and cash returns than today’s share price seems to reflect.

"Key Takeaways: Bullish analysts expect Afya to use the planned merger with Yduqs, the expansion in medical and broader health education and the cash generation seen in H1 2026 to support continued growth in revenue, EBITDA and free cash flow for the combined group. The main thing that has to go right is that Afya and Yduqs actually capture the projected BRL 2.0 to 2.2b in net synergies and execute on AI driven upgrades across physician solutions while managing tax and regulatory changes around medical education and Pillar Two."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

How Could You Get There Earlier?

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 26% below our estimate - builds a low cost digital banking platform as customers adopt higher ARPAC services.
• Company 2 - 30% below our estimate - expands a tech driven lending system as a planned bank acquisition reshapes its funding model.
• Company 3 - 33% below our estimate - grows coconut based beverage volumes as private label and international channels scale alongside brands.

Those are three of them. See every one of the 38 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com